阿奇霉素、克拉霉素、红霉素和四环素对13株肺炎衣原体的体外活性
In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae.
作者信息
Welsh L, Gaydos C, Quinn T C
机构信息
Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
出版信息
Antimicrob Agents Chemother. 1996 Jan;40(1):212-4. doi: 10.1128/AAC.40.1.212.
Abstract
Thirteen strains of Chlamydia pneumoniae were evaluated for their in vitro susceptibilities to azithromycin, clarithromycin, erythromycin, and tetracycline. The MIC ranges were 0.125 to 0.5 micrograms/ml for azithromycin, 0.031 to 1.0 micrograms/ml for clarithromycin, 0.125 to 1.0 micrograms/ml for erythromycin, and 0.25 to 1.0 micrograms/ml for tetracycline. The ranges for the minimal lethal concentrations were 0.125 to 0.5 micrograms/ml for azithromycin, 0.031 to 1.0 micrograms/ml for clarithromycin, 0.125 to 1.0 micrograms/ml for erythromycin, and 0.25 to 1.0 micrograms/ml for tetracycline. Clarithromycin and azithromycin were the most active antibiotics against C. pneumoniae in vitro.
摘要
对13株肺炎衣原体菌株进行了体外对阿奇霉素、克拉霉素、红霉素和四环素敏感性的评估。阿奇霉素的MIC范围为0.125至0.5微克/毫升，克拉霉素为0.031至1.0微克/毫升，红霉素为0.125至1.0微克/毫升，四环素为0.25至1.0微克/毫升。最小致死浓度范围为：阿奇霉素0.125至0.5微克/毫升，克拉霉素0.031至1.0微克/毫升，红霉素0.125至1.0微克/毫升，四环素0.25至1.0微克/毫升。克拉霉素和阿奇霉素是体外抗肺炎衣原体最有效的抗生素。
相似文献
1
In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae.阿奇霉素、克拉霉素、红霉素和四环素对13株肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1996 Jan;40(1):212-4. doi: 10.1128/AAC.40.1.212.
2
In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.阿奇霉素、克拉霉素、左旋氧氟沙星及其他抗生素对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1992 Jul;36(7):1573-4. doi: 10.1128/AAC.36.7.1573.
3
In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae.阿奇霉素、克拉霉素及其他抗生素对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1996 Nov;40(11):2669-70. doi: 10.1128/AAC.40.11.2669.
4
In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae.阿奇霉素（CP - 62,993）对沙眼衣原体和肺炎衣原体的体外活性。
Antimicrob Agents Chemother. 1993 Sep;37(9):1746-8. doi: 10.1128/AAC.37.9.1746.
5
In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae.阿奇霉素、红霉素和四环素对沙眼衣原体和肺炎衣原体活性的体外评估
Antimicrob Agents Chemother. 1992 Feb;36(2):291-4. doi: 10.1128/AAC.36.2.291.
6
Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci.克拉霉素、红霉素和阿奇霉素对青霉素敏感及耐药肺炎球菌的比较活性
Antimicrob Agents Chemother. 1996 Aug;40(8):1950-2. doi: 10.1128/AAC.40.8.1950.
7
In vitro activity of trovafloxacin against Chlamydia pneumoniae.曲伐沙星对肺炎衣原体的体外活性。
Antimicrob Agents Chemother. 1997 Sep;41(9):2033-4. doi: 10.1128/AAC.41.9.2033.
8
In vitro evaluation of activities of azithromycin, clarithromycin and sparfloxacin against Chlamydia trachomatis.阿奇霉素、克拉霉素和司帕沙星对沙眼衣原体活性的体外评估
Pathol Biol (Paris). 1993 Apr;41(4):313-5.
9
Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia.肺炎患儿肺炎衣原体分离株对克拉霉素和红霉素的敏感性
Antimicrob Agents Chemother. 1994 Jul;38(7):1588-9. doi: 10.1128/AAC.38.7.1588.
10
In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.新型酮内酯类抗生素HMR 3647对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1998 Jun;42(6):1515-6. doi: 10.1128/AAC.42.6.1515.
引用本文的文献
1
Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.奥马环素：一种新型口服和静脉注射氨甲基环素抗生素药物。
Drugs. 2020 Feb;80(3):285-313. doi: 10.1007/s40265-020-01257-4.
2
Antibacterial activity of biosecur(®) citrus extract surface cleaner against Vibrio vulnificus.生物安全（®）柑橘提取物表面清洁剂对创伤弧菌的抗菌活性。
Open Microbiol J. 2013 Nov 8;7:130-4. doi: 10.2174/1874285801307010130. eCollection 2013.
3
Chlamydia pneumoniae resists antibiotics in lymphocytes.肺炎衣原体对淋巴细胞中的抗生素具有抗性。
Antimicrob Agents Chemother. 2003 Jun;47(6):1972-5. doi: 10.1128/AAC.47.6.1972-1975.2003.
4
Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.住院儿科患者常用的抗菌和抗真菌药物：基于临床药代动力学对治疗的影响
Paediatr Drugs. 2001;3(10):733-61. doi: 10.2165/00128072-200103100-00003.
5
In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations.德国患者肺炎衣原体分离株的体外药敏性及抗生素联合用药的协同活性。
Antimicrob Agents Chemother. 1999 Jul;43(7):1808-10. doi: 10.1128/AAC.43.7.1808.
6
Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome--a randomized study.阿奇霉素：单剂量1.5克治疗非典型肺炎综合征患者的随机研究。
Infection. 1999 May-Jun;27(3):198-202. doi: 10.1007/BF02561528.
7
Azithromycin. A review of its use in paediatric infectious diseases.阿奇霉素。其在儿科传染病中应用的综述。
Drugs. 1998 Aug;56(2):273-97. doi: 10.2165/00003495-199856020-00014.
8
Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.克拉霉素。免疫功能正常患者呼吸道感染治疗中其疗效的综述。
Drugs. 1997 Jun;53(6):973-1004. doi: 10.2165/00003495-199753060-00006.
本文引用的文献
1
New oral macrolide and fluoroquinolone antibiotics: an overview of pharmacokinetics, interactions, and safety.新型口服大环内酯类和氟喹诺酮类抗生素：药代动力学、相互作用及安全性概述
Clin Infect Dis. 1993 Aug;17 Suppl 1:S192-9. doi: 10.1093/clinids/17.supplement_1.s192.
2
Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia.肺炎患儿肺炎衣原体分离株对克拉霉素和红霉素的敏感性
Antimicrob Agents Chemother. 1994 Jul;38(7):1588-9. doi: 10.1128/AAC.38.7.1588.
3
Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae.肺炎衣原体所致感染的抗菌药敏性及治疗
Antimicrob Agents Chemother. 1994 Sep;38(9):1873-8. doi: 10.1128/AAC.38.9.1873.
4
Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.小儿社区获得性肺炎中的肺炎支原体和肺炎衣原体：克拉霉素与琥乙红霉素的疗效及安全性比较
Pediatr Infect Dis J. 1995 Jun;14(6):471-7. doi: 10.1097/00006454-199506000-00002.
5
Community-acquired pneumonia: impact of immune status.
Am J Respir Crit Care Med. 1995 Oct;152(4 Pt 1):1309-15. doi: 10.1164/ajrccm.152.4.7551387.
6
Relative resistance to erythromycin in Chlamydia trachomatis.沙眼衣原体对红霉素的相对耐药性。
Antimicrob Agents Chemother. 1980 Nov;18(5):696-8. doi: 10.1128/AAC.18.5.696.
7
A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections.一种新的鹦鹉热衣原体菌株，TWAR，在急性呼吸道感染中分离得到。
N Engl J Med. 1986 Jul 17;315(3):161-8. doi: 10.1056/NEJM198607173150305.
8
In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis.CP-62,993、红霉素、克林霉素和四环素对沙眼衣原体的体外评估
Antimicrob Agents Chemother. 1987 May;31(5):811-2. doi: 10.1128/AAC.31.5.811.
9
In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR).肺炎衣原体（衣原体属TWAR株）的体外药敏试验
Antimicrob Agents Chemother. 1989 Sep;33(9):1634-5. doi: 10.1128/AAC.33.9.1634.
10
A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.一种新的呼吸道病原体：肺炎衣原体TWAR株。
J Infect Dis. 1990 Apr;161(4):618-25. doi: 10.1093/infdis/161.4.618.
Zotero 插件